
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Joshua Sabari, MD, assistant professor of medicine and medical oncology at Perlmutter Cancer Center NYU Langone Health, presented data that examined the development of zongertinib (BI …